Technical Analysis for ALVR - AlloVir, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Inside Day | Range Contraction | 0.00% | |
| Gapped Down | Weakness | 0.00% | |
| MACD Bullish Signal Line Cross | Bullish | -1.38% | |
| BB Squeeze Ended | Range Expansion | -1.38% | |
| Up 3 Days in a Row | Strength | -1.38% | |
| Upper Bollinger Band Touch | Strength | -1.38% | |
| Crossed Above 20 DMA | Bullish | 2.23% | |
| MACD Bullish Centerline Cross | Bullish | 2.23% | |
| Bollinger Band Squeeze | Range Contraction | 2.23% | |
| Narrow Range Bar | Range Contraction | 2.23% |
| Alert | Time |
|---|---|
| Possible Inside Day | about 13 hours ago |
| Gap Down Closed | about 15 hours ago |
| 60 Minute Opening Range Breakout | about 15 hours ago |
| Gap Down Partially Closed | about 17 hours ago |
| Gapped Down (Partial) | about 18 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/02/2024
AlloVir is a leading late clinical-stage cell therapy company with a focus on restoring natural immunity against life-threatening viral diseases in patients with severely weakened immune systems. The company’s innovative and proprietary technology platforms leverage off-the-shelf, allogeneic, multi-virus specific T cells targeting devastating viruses for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. AlloVir’s technology and manufacturing process enables the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. The company is advancing multiple mid- and late-stage clinical trials across its product portfolio.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biology Immune System Stem Cell Cell Therapy Cell Biology Gene Therapy Manufacturing Process Viruses Virus Viral Disease Immunity Covid 19 Zoonoses
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biology Immune System Stem Cell Cell Therapy Cell Biology Gene Therapy Manufacturing Process Viruses Virus Viral Disease Immunity Covid 19 Zoonoses
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 6.1 |
| 52 Week Low | 0.6231 |
| Average Volume | 586,599 |
| 200-Day Moving Average | 1.68 |
| 50-Day Moving Average | 0.74 |
| 20-Day Moving Average | 0.76 |
| 10-Day Moving Average | 0.76 |
| Average True Range | 0.04 |
| RSI (14) | 55.56 |
| ADX | 14.47 |
| +DI | 19.68 |
| -DI | 9.99 |
| Chandelier Exit (Long, 3 ATRs) | 0.73 |
| Chandelier Exit (Short, 3 ATRs) | 0.83 |
| Upper Bollinger Bands | 0.79 |
| Lower Bollinger Band | 0.73 |
| Percent B (%b) | 0.79 |
| BandWidth | 9.13 |
| MACD Line | 0.01 |
| MACD Signal Line | 0.00 |
| MACD Histogram | 0.0027 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 0.81 | ||||
| Resistance 3 (R3) | 0.81 | 0.80 | 0.81 | ||
| Resistance 2 (R2) | 0.80 | 0.79 | 0.80 | 0.81 | |
| Resistance 1 (R1) | 0.79 | 0.79 | 0.80 | 0.79 | 0.80 |
| Pivot Point | 0.78 | 0.78 | 0.78 | 0.78 | 0.78 |
| Support 1 (S1) | 0.77 | 0.77 | 0.77 | 0.77 | 0.76 |
| Support 2 (S2) | 0.76 | 0.77 | 0.76 | 0.75 | |
| Support 3 (S3) | 0.75 | 0.76 | 0.75 | ||
| Support 4 (S4) | 0.75 |
